# Impact of polypharmacy on oral health in the elderly: challenges and management

**Authors:** Sowmya Halasabalu Kalgeri, SunilKumar Bheemasamudra Balaraj, Ashwini Tumkur Shivakumar, Vidya G. Doddawad, Deepa Basapur Vijayakumar, Shalini H. S., Anupama Aradya, Parinitha Mysore Shankar, Nagabhushana Doggalli, Sumukh R. Bharadwaj

PMC · DOI: 10.3389/fdmed.2026.1758771 · Frontiers in Dental Medicine · 2026-02-23

## TL;DR

Polypharmacy in elderly people can harm oral health, and managing it requires teamwork among healthcare providers.

## Contribution

Proposes an interprofessional management framework for dental practitioners to address oral health risks from polypharmacy in older adults.

## Key findings

- Polypharmacy affects 30%–44% of older adults globally, with higher rates in those with chronic diseases.
- Medications like anticholinergics and antihypertensives are linked to dry mouth and oral complications.
- Interdisciplinary care involving dentists, physicians, and pharmacists is essential for managing polypharmacy-related oral issues.

## Abstract

With increasing life expectancy and multimorbidity, polypharmacy—commonly defined as the concurrent use of five or more medications—has become highly prevalent in older adults and poses substantial risks for oral health. This narrative review aimed to synthesize contemporary evidence on the epidemiology, pharmacological mechanisms, and oral manifestations of polypharmacy in geriatric populations, and to propose an interprofessional management framework for dental practitioners in 2025 care settings. Recent epidemiological data indicate that polypharmacy affects more than 30%–44% of older adults globally, with even higher rates among those with cardiovascular disease, diabetes, and multimorbidity. Medications with anticholinergic burden, as well as many antihypertensive and psychotropic agents, are strongly associated with salivary gland hypofunction and xerostomia, which in turn contribute to rampant caries, oral candidiasis, mucosal lesions, dysgeusia, periodontal complications, and drug-induced gingival overgrowth. Diagnostic and therapeutic challenges are amplified by underreporting of symptoms, cognitive impairment, and fragmented medical–dental care pathways. Evidence supports a preventive and interdisciplinary approach that includes structured medication review and deprescribing in collaboration with physicians and pharmacists, optimization of salivary function using sialogogues and saliva substitutes, prescription of high-fluoride toothpastes, and tailored oral hygiene and dietary counseling with caregiver engagement. Dentists are strategically positioned to detect medication-related oral conditions, trigger timely medication optimization, and coordinate ongoing care. A structured, multidisciplinary model integrating dental, medical, and pharmacy services is essential to mitigate the oral and systemic consequences of polypharmacy and to preserve function and quality of life in aging populations.

## Linked entities

- **Diseases:** cardiovascular disease (MONDO:0004995), diabetes (MONDO:0005015)

## Full-text entities

- **Genes:** SLC12A1 (solute carrier family 12 member 1) [NCBI Gene 6557] {aka BSC, BSC-1, BSC1, CCC2, NKCC2}
- **Diseases:** anxiety (MESH:D001007), denture stomatitis (MESH:D013282), mucosal irritation (MESH:D001523), salivary gland hypofunction (MESH:D000309), Sjogren's syndrome (MESH:D012859), diabetes (MESH:D003920), lichenoid reactions (MESH:D017512), Dysgeusia (MESH:D004408), painful lesions (MESH:D010146), oral conditions (MESH:D020763), inflammatory lesions (MESH:D007249), mucosal trauma (MESH:D014947), gastroesophageal reflux (MESH:D005764), Oral Ulceration (MESH:D019226), epulis fissuratum (MESH:D005882), vomiting (MESH:D014839), systemic disease (MESH:D034721), halitosis (MESH:D006209), micronutrient deficits (MESH:D009461), Burning mouth syndrome (MESH:D002054), fatigue (MESH:D005221), mucosal lesions (MESH:D009059), autoimmune conditions (MESH:D001327), enamel erosion (MESH:D014077), dizziness (MESH:D004244), mucosal ulcers (MESH:D014456), infections (MESH:D007239), cardiovascular disease (MESH:D002318), Gingival overgrowth (MESH:D019214), salivary gland dysfunction (MESH:D012466), Nutritional deficiencies (MESH:D044342), mucosal fragility (MESH:D002873), caries (MESH:D003731), mucosal symptoms (MESH:D012818), Cognitive impairment (MESH:D003072), fungal infection (MESH:D009181), periodontal complications (MESH:D010510), candidiasis (MESH:D002177), Enlargement (MESH:D006332), heart disease (MESH:D006331), dementia (MESH:D003704), Glossodynia (MESH:D005926), Oral Candidiasis (MESH:D002180), Dry Mouth (MESH:D014987), Mucositis (MESH:D052016)
- **Chemicals:** nifedipine (MESH:D009543), sugar (MESH:D000073893), Thiazide (MESH:D049971), chloride (MESH:D002712), fluoride (MESH:D005459), miconazole (MESH:D008825), bicarbonate (MESH:D001639), phenytoin (MESH:D010672), benzodiazepines (MESH:D001569), pilocarpine (MESH:D010862), cyclosporine (MESH:D016572), agents (-), cevimeline (MESH:C059240), triamcinolone acetonide (MESH:D014222), bisphosphonates (MESH:D004164), calcium (MESH:D002118), nystatin (MESH:D009761), fluconazole (MESH:D015725)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12968186/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12968186/full.md

## References

51 references — full list in the complete paper: https://tomesphere.com/paper/PMC12968186/full.md

---
Source: https://tomesphere.com/paper/PMC12968186